However, in a meta‐analysis comprising 16 AML studies [114], TET2 mutation was associated with a significant adverse impact on both OS (HR [95% CI] = 1.386 [1.217–1.577], p < 0.001) (Table 2) and event free survival (EFS) (HR [95% CI] = 1.594 [1.187–2.141], p = 0.002). The gene discussed is TET2; the disease is acute myeloid leukemia.